Stéphane Champiat, MD, PhD, Reviews Results With IL-2/IL15 Superagonist SOT101 From AURELIO-03 Trial


Stéphane Champiat, MD, PhD, spoke about the results of the AURELIO-03 trial with SOT101 and pembrolizumab for patients with advanced solid tumors.

During the American Association for Cancer Research (AACR) 2022 Annual Meeting, CancerNetwork® spoke with Stéphane Champiat, MD, PhD, assistant professor in the Drug Development Department of Gustave Roussy Cancer Campus in Paris, France, about the recently reported results of the phase 2 dose-escalation AURELIO-3 trial (NCT04234113) which examined SOT101, an interleukin (IL)–2/IL-15 superagonist, in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors. Safety and efficacy results were reported at the meeting.


The SOT101 study is evaluating the safety and primary results of efficacy [of the agent] in combination with pembrolizumab. SOT101 is a fusion protein containing IL-15 in the Sushi domain of IL-15 receptor α. Therefore, it has enhanced [ability] to activate T cells or NK [natural killer] cells and avoid activating Tregs [T regulatory] cells compared with classical IL-2.

[SOT101] is administered subcutaneously and pembrolizumab is administered [intravenously]. The study included multiple solid tumor typess. Most of the patients who were treated in that study had primary or secondary resistance to classical anti–PD-1 or anti–PD-L1 [agents]. The translational data has shown that SOT101 is able to activate NK cells at very early dose and activate CD8-positive T cells later with a higher dose.

There was no relevant activation of Tregs. In terms of safety, the safety profile was overall pretty good. Most of the adverse [effects] are grade 1 and 2 and are transient and do not necessarily require corticosteroids. There was no MTD [maximum tolerated dose] identified at the higher dose level. The recommended phase 2 dose was 12 mg/kg based on safety and [pharmacodynamic] data. Overall, the activity is showing several responses among the 16 evaluable patients. There was 1 complete response in [patients with] mesothelioma and 4 partial responses other tumor types. Overall, 12 of 16 of those patients were having the benefit from the treatment either through prolonged stable disease or partial or complete response. The longest response that was observed with this treatment so far is more than 14 weeks.


Champiat S, Marabelle A, Galvao V, et al. SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: interim safety and efficacy results from the AURELIO-03 dose escalation trial. Presented at the 2022 American Association for Cancer Research Annual Meeting. New Orleans, LA. April 8-13, 2022.

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.